MeiraGTx Holdings plc
A clinical-stage genetic medicine company treating eye, salivary, and CNS disorders.
MGTX | US
Overview
Corporate Details
- ISIN(s):
- KYG596651029
- LEI:
- Country:
- United States of America
- Address:
- 655 THIRD AVENUE, 10017 NEW YORK
- Website:
- https://meiragtx.com/
- Sector:
- Manufacturing
Description
MeiraGTx Holdings plc is a clinical-stage genetic medicine company developing therapies for both rare and prevalent diseases. The company's primary focus areas include disorders of the eye, salivary gland, and central nervous system. MeiraGTx utilizes a proprietary riboswitch gene regulation platform designed to provide precise spatial and temporal control of gene expression. As a vertically integrated entity, it possesses end-to-end capabilities, including its own cGMP manufacturing facilities, to support a broad pipeline of therapeutic candidates. The company has multiple programs in clinical development, with several in late-stage trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all MeiraGTx Holdings plc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MeiraGTx Holdings plc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MeiraGTx Holdings plc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
